Abstract

The addition of rituximab to anthracycline-based chemotherapy provides a superior outcome for patients with grade 3 follicular lymphoma (FL3), and it is important to differentiate FL3B from FL3A and FL3C since patients with FL3B have an outcome similar to those with DLBCL. Background The combination of rituximab with chemotherapy has improved the outcome of patients with follicular lymphoma (FL). However, data on Grade 3 FL (FL3) and its subtypes are lacking. The aims of the study were to determine: (1) the clinical features and outcome of patients with FL3 treated with rituximab and anthracycline-based chemotherapy; and (2) the clinical significance of the 3 subtypes of FL3. Patients and Methods Eighty-seven patients with Grade 1/2 FL, 84 with FL3 including 46 FL3A, 17 FL3B, and 21 follicular large cleaved cell (FL3C), and 411 patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab and anthracycline-based chemotherapy, and a historical cohort of 167 patients with FL3 who received only anthracycline-based chemotherapy (FL3*) were included in this retrospective study. Results The FL3 group had a significantly better overall survival (OS) and event-free survival (EFS) compared with those with FL3* or DLBCL. No significant differences in OS were found among the 3 subtypes of FL3. However, patients with FL3B had a shorter EFS than those with FL3A and FL3C. Moreover, patients with FL3B had an outcome similar to those with DLBCL, whereas patients with FL3A and 3C had significantly better outcomes than those with DLBCL. Less than 50% of the patients with FL3B and less than 20% of the patients with FL3A and 3C have relapsed, and relapses were uncommon after 5 years. Conclusion The use of rituximab with anthracycline-based chemotherapy significantly improved the survival of patients with FL3 and should be considered the benchmark by which other therapies for FL3 are evaluated in the future.

Original languageEnglish (US)
Pages (from-to)488-497.e2
JournalClinical Lymphoma, Myeloma and Leukemia
Volume17
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Follicular Lymphoma
Anthracyclines
Lymphoma, Large B-Cell, Diffuse
Drug Therapy
Therapeutics
Rituximab
Disease-Free Survival
Survival
Benchmarking

Keywords

  • Anthracycline
  • Follicular lymphoma
  • Grade 3
  • Non-Hodgkin lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{62be7b26f39a425b86d43dfb29576107,
title = "Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy",
abstract = "The addition of rituximab to anthracycline-based chemotherapy provides a superior outcome for patients with grade 3 follicular lymphoma (FL3), and it is important to differentiate FL3B from FL3A and FL3C since patients with FL3B have an outcome similar to those with DLBCL. Background The combination of rituximab with chemotherapy has improved the outcome of patients with follicular lymphoma (FL). However, data on Grade 3 FL (FL3) and its subtypes are lacking. The aims of the study were to determine: (1) the clinical features and outcome of patients with FL3 treated with rituximab and anthracycline-based chemotherapy; and (2) the clinical significance of the 3 subtypes of FL3. Patients and Methods Eighty-seven patients with Grade 1/2 FL, 84 with FL3 including 46 FL3A, 17 FL3B, and 21 follicular large cleaved cell (FL3C), and 411 patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab and anthracycline-based chemotherapy, and a historical cohort of 167 patients with FL3 who received only anthracycline-based chemotherapy (FL3*) were included in this retrospective study. Results The FL3 group had a significantly better overall survival (OS) and event-free survival (EFS) compared with those with FL3* or DLBCL. No significant differences in OS were found among the 3 subtypes of FL3. However, patients with FL3B had a shorter EFS than those with FL3A and FL3C. Moreover, patients with FL3B had an outcome similar to those with DLBCL, whereas patients with FL3A and 3C had significantly better outcomes than those with DLBCL. Less than 50{\%} of the patients with FL3B and less than 20{\%} of the patients with FL3A and 3C have relapsed, and relapses were uncommon after 5 years. Conclusion The use of rituximab with anthracycline-based chemotherapy significantly improved the survival of patients with FL3 and should be considered the benchmark by which other therapies for FL3 are evaluated in the future.",
keywords = "Anthracycline, Follicular lymphoma, Grade 3, Non-Hodgkin lymphoma, Rituximab",
author = "Ji Yuan and Greiner, {Timothy Charles} and Kai Fu and Smith, {Lynette M} and Patricia Aoun and Chan, {Wing C.} and Bierman, {Philip Jay} and Bociek, {Robert G} and Vose, {Julie Marie} and Armitage, {James Olen} and Weisenburger, {Dennis D.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.clml.2017.06.006",
language = "English (US)",
volume = "17",
pages = "488--497.e2",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "8",

}

TY - JOUR

T1 - Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy

AU - Yuan, Ji

AU - Greiner, Timothy Charles

AU - Fu, Kai

AU - Smith, Lynette M

AU - Aoun, Patricia

AU - Chan, Wing C.

AU - Bierman, Philip Jay

AU - Bociek, Robert G

AU - Vose, Julie Marie

AU - Armitage, James Olen

AU - Weisenburger, Dennis D.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - The addition of rituximab to anthracycline-based chemotherapy provides a superior outcome for patients with grade 3 follicular lymphoma (FL3), and it is important to differentiate FL3B from FL3A and FL3C since patients with FL3B have an outcome similar to those with DLBCL. Background The combination of rituximab with chemotherapy has improved the outcome of patients with follicular lymphoma (FL). However, data on Grade 3 FL (FL3) and its subtypes are lacking. The aims of the study were to determine: (1) the clinical features and outcome of patients with FL3 treated with rituximab and anthracycline-based chemotherapy; and (2) the clinical significance of the 3 subtypes of FL3. Patients and Methods Eighty-seven patients with Grade 1/2 FL, 84 with FL3 including 46 FL3A, 17 FL3B, and 21 follicular large cleaved cell (FL3C), and 411 patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab and anthracycline-based chemotherapy, and a historical cohort of 167 patients with FL3 who received only anthracycline-based chemotherapy (FL3*) were included in this retrospective study. Results The FL3 group had a significantly better overall survival (OS) and event-free survival (EFS) compared with those with FL3* or DLBCL. No significant differences in OS were found among the 3 subtypes of FL3. However, patients with FL3B had a shorter EFS than those with FL3A and FL3C. Moreover, patients with FL3B had an outcome similar to those with DLBCL, whereas patients with FL3A and 3C had significantly better outcomes than those with DLBCL. Less than 50% of the patients with FL3B and less than 20% of the patients with FL3A and 3C have relapsed, and relapses were uncommon after 5 years. Conclusion The use of rituximab with anthracycline-based chemotherapy significantly improved the survival of patients with FL3 and should be considered the benchmark by which other therapies for FL3 are evaluated in the future.

AB - The addition of rituximab to anthracycline-based chemotherapy provides a superior outcome for patients with grade 3 follicular lymphoma (FL3), and it is important to differentiate FL3B from FL3A and FL3C since patients with FL3B have an outcome similar to those with DLBCL. Background The combination of rituximab with chemotherapy has improved the outcome of patients with follicular lymphoma (FL). However, data on Grade 3 FL (FL3) and its subtypes are lacking. The aims of the study were to determine: (1) the clinical features and outcome of patients with FL3 treated with rituximab and anthracycline-based chemotherapy; and (2) the clinical significance of the 3 subtypes of FL3. Patients and Methods Eighty-seven patients with Grade 1/2 FL, 84 with FL3 including 46 FL3A, 17 FL3B, and 21 follicular large cleaved cell (FL3C), and 411 patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab and anthracycline-based chemotherapy, and a historical cohort of 167 patients with FL3 who received only anthracycline-based chemotherapy (FL3*) were included in this retrospective study. Results The FL3 group had a significantly better overall survival (OS) and event-free survival (EFS) compared with those with FL3* or DLBCL. No significant differences in OS were found among the 3 subtypes of FL3. However, patients with FL3B had a shorter EFS than those with FL3A and FL3C. Moreover, patients with FL3B had an outcome similar to those with DLBCL, whereas patients with FL3A and 3C had significantly better outcomes than those with DLBCL. Less than 50% of the patients with FL3B and less than 20% of the patients with FL3A and 3C have relapsed, and relapses were uncommon after 5 years. Conclusion The use of rituximab with anthracycline-based chemotherapy significantly improved the survival of patients with FL3 and should be considered the benchmark by which other therapies for FL3 are evaluated in the future.

KW - Anthracycline

KW - Follicular lymphoma

KW - Grade 3

KW - Non-Hodgkin lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85028295594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028295594&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2017.06.006

DO - 10.1016/j.clml.2017.06.006

M3 - Article

VL - 17

SP - 488-497.e2

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 8

ER -